Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHRA Reinforces Brexit Road-Map, Indian Firms Expect Tough Transition

Executive Summary

The MHRA highlighted at a recent conference in India the key changes that await pharma in the event of a no-deal Brexit, and the agency’s general readiness in that scenario, including putting in place its own IT systems such as a UK national replacement for the EudraGMDP.

You may also be interested in...

Goodbye To All That: EMA Leaves London After 24 years

March 1 saw the official departure of the European Medicines Agency for Amsterdam. The move from London, which is a result of the UK's decision to leave the EU, has caused huge upheaval for the agency, which has been in the UK capital since it was created in 1995.

How The UK Regulatory System Would Work In A No-Deal Brexit – Part 2

In this second article on the regulations published by the government on how the UK would regulate medicines in a “no-deal” Brexit scenario, we look at what is being proposed for areas such as pediatric investigation plans, orphan medicines, pharmacovigilance, parallel trade, generics approvals, and good manufacturing and distribution practices.

How The UK Regulatory System Would Work In A No-Deal Brexit – Part 1

Regulations that would allow the UK MHRA to work as a standalone regulator in the event of a no-deal Brexit have been laid before parliament. They cover a host of areas including new drug approval procedures, conversion of existing EU marketing authorizations into UK ones, pediatric and orphan exclusivities, imported medicines, and regulatory fees.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts